InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapies targeting the complement system, announced the successful completion of its public offering. The offering comprised 8,250,000 ordinary shares at $2.00 per share and pre-funded warrants for up to 6,750,000 ordinary shares. Each warrant’s price matched the share price, less $0.001 (the warrant’s exercise price). Gross proceeds totaled approximately $30 million, before underwriting discounts and expenses. Underwriters also hold a 30-day option to purchase an additional 2,250,000 shares at the public offering price, less the underwriting discount.

Net proceeds will primarily fund clinical development of vilobelimab and INF904, and for general corporate purposes.

Guggenheim Securities, LLC served as book-running manager. H.C. Wainwright & Co. and Lucid Capital Markets, LLC were co-lead managers.

The U.S. Securities and Exchange Commission (SEC) declared effective a shelf registration statement for the shares and warrants on July 11, 2023. The offering was conducted solely via prospectus and prospectus supplement, available on the SEC website (www.sec.gov) and from Guggenheim Securities, LLC (contact details provided).

This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities where prohibited by law.

About InflaRx N.V.:

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company developing anti-inflammatory treatments using proprietary anti-C5a and anti-C5aR technologies. These technologies target C5a, a key inflammatory mediator. The company’s lead candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody showing clinical efficacy and tolerability. InflaRx is also developing INF904, an oral C5a receptor inhibitor. Founded in 2007, InflaRx operates in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more information, visit www.inflarx.com.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals, Inc. (USA) are wholly owned subsidiaries of InflaRx N.V.

Contacts:

InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de 

MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. These statements, often indicated by terms like “may,” “will,” “should,” “expect,” etc., are subject to risks and uncertainties. See our SEC filings for details on risk factors. These statements reflect our current views and are not guarantees of future results. We do not undertake to update these statements.